EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis

Proton Rahman, Iain B McInnes, Atul Deodhar, Georg Schett, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin und 1 weitere

Clinical Rheumatology · 2024

DOI: 10.1007/s10067-024-06921-8 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Clinical Rheumatology, 2024. Verfasst von Proton Rahman und 12 weiteren Autor:innen. Beteiligte Einrichtung: Memorial University of Newfoundland, St. Johns, NF, Canada. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Psoriatic, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the association between enthesitis resolution (ER) and dactylitis resolution (DR) and meaningful improvements in patient-reported outcomes (PROs) among biologic-naïve patients with PsA receiving guselkumab in the DISCOVER-2 study.

Methods

Enthesitis and dactylitis, characteristic lesions of PsA, were evaluated by independent assessors using the Leeds Enthesitis Index (range, 0–6) and Dactylitis Severity Score (range, 0–60). Proportions of patients with ER or DR (score = 0) among those with score > 0 at baseline were determined at weeks 24, 52, and 100. PROs included: fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-Fatigue]), pain (0–100 visual analog scale), physical function (Health Assessment Questionnaire-Disability Index [HAQ-DI]), and health-related quality of life (36-item Short-Form Health Survey physical/mental component summary [SF-36 PCS/MCS]). Meaningful responses were defined as: improvements of ≥ 4 for FACIT-Fatigue, ≥ 0.35 for HAQ-DI, and ≥ 5 for SF-36 PCS/MCS and absolute scores of ≤ 15 for minimal pain and ≤ 0.5 for normalized HAQ-DI. Associations between ER/DR status and PRO response status were tested using a Chi-square test.

Results

Guselkumab-treated patients with ER were more likely than those without ER to achieve minimal pain ( p < 0.001), normalized HAQ-DI ( p < 0.001), and PCS response ( p < 0.05) at weeks 24, 52, and 100. Patients with DR were more likely than those without DR to achieve FACIT-Fatigue response at week 24 and week 52 (both p ≤ 0.01) and minimal pain at week 24 and normalized HAQ-DI at week 52 (both p ≤ 0.03).

Conclusion

In biologic-naïve patients with active PsA treated with guselkumab, achieving ER or DR was associated with durable improvements in selected PROs, including those of high importance to patients.

Trial registration

ClinicalTrials.gov ( https://clinicaltrials.gov ) NCT03158285; Registered: May 16, 2017. Key Points • At week 100, 65% and 76% of guselkumab-treated patients achieved enthesitis and dactylitis resolution (ER/DR). • Achieving ER was associated with achieving DR and vice versa through the end of study. • Achieving ER or DR was associated with durable and meaningful improvements in selected patient-reported outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, PsoriaticBiological ProductsEnthesopathyHumansPainPatient Reported Outcome MeasuresQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

BiologicDactylitisEnthesitisGuselkumabPsoriatic arthritis

Substanzen

Antibodies, Monoclonal, HumanizedAntirheumatic AgentsBiological Productsguselkumab

Autor:innen und Institutionen

  • Memorial University of Newfoundland, St. Johns, NF, Canada.
  • University of Glasgow, Glasgow, UK.
  • Oregon Health & Science University, Portland, OR, USA.
  • FAU Erlangen-Nürnberg and Universitätsklinikum, Erlangen, Germany.
  • Rheumatology Research, Providence Swedish Medical Center, Seattle, WA, USA.
  • University of Washington School of Medicine, Seattle, WA, USA.

Förderung

  • Janssen Research and Development

Zitieren

APA

Rahman, P., McInnes, I. B., Deodhar, A., Schett, G., Mease, P. J., Shawi, M., Cua, D. J., Sherlock, J. P., Kollmeier, A. P., Xu, X. L., Sheng, S., Ritchlin, C. T., & McGonagle, D. (2024). Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical Rheumatology. https://doi.org/10.1007/s10067-024-06921-8

Vancouver

Rahman P, McInnes IB, Deodhar A, Schett G, Mease PJ, Shawi M, et al. Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical Rheumatology. 2024. doi:10.1007/s10067-024-06921-8

BibTeX
@article{Rahman2024,
  author = {Rahman, Proton and McInnes, Iain B and Deodhar, Atul and Schett, Georg and Mease, Phillip J and Shawi, May and Cua, Daniel J and Sherlock, Jonathan P and Kollmeier, Alexa P and Xu, Xie L and Sheng, Shihong and Ritchlin, Christopher T and McGonagle, Dennis},
  title = {Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis},
  journal = {Clinical Rheumatology},
  year = {2024},
  doi = {10.1007/s10067-024-06921-8}
}
Kostenlos starten →